Cargando…

Yao medicine Amydrium hainanense suppresses hepatic fibrosis by repressing hepatic stellate cell activation via STAT3 signaling

Ethnopharmacological relevance: Hepatic fibrosis (HF) occurs in response to chronic liver injury and may easily develop into irreversible liver cirrhosis or even liver cancer. Amydrium hainanense water extract (AHWE) is a water-soluble component extracted from the Yao medicine Amydrium hainanense (H...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Bingmin, Huang, Lan, Wang, Yange, Zeng, Lishan, Lin, Ying, Li, Jingyan, Wang, Shaogui, Zhang, Guifang, An, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794994/
https://www.ncbi.nlm.nih.gov/pubmed/36588728
http://dx.doi.org/10.3389/fphar.2022.1043022
_version_ 1784860155632943104
author Wu, Bingmin
Huang, Lan
Wang, Yange
Zeng, Lishan
Lin, Ying
Li, Jingyan
Wang, Shaogui
Zhang, Guifang
An, Lin
author_facet Wu, Bingmin
Huang, Lan
Wang, Yange
Zeng, Lishan
Lin, Ying
Li, Jingyan
Wang, Shaogui
Zhang, Guifang
An, Lin
author_sort Wu, Bingmin
collection PubMed
description Ethnopharmacological relevance: Hepatic fibrosis (HF) occurs in response to chronic liver injury and may easily develop into irreversible liver cirrhosis or even liver cancer. Amydrium hainanense water extract (AHWE) is a water-soluble component extracted from the Yao medicine Amydrium hainanense (H.Li, Y.Shiao & S.L.Tseng) H.Li, which is commonly used for treating inflammatory diseases in folk. Previous evidence suggested that AHWE significantly inhibited hepatic stellate cell activation. However, little is known regarding the therapeutic effect of AHWE in HF and its underlying action mechanism. Objective: Investigation of the therapeutic effect of AHWE in HF and its underlying mechanism. Methods: The therapeutic effect of AHWE was tested in vivo using an HF mouse model via an intraperitoneal injection of carbon tetrachloride (CCl(4)). Histological evaluation of liver injury and fibrosis were tested by H&E staining and Masson’s trichrome staining. Serum levels of ALT, AST, collagen type I (Col I), and hydroxyproline (HYP) were measured. The mRNA expression of liver fibrotic and inflammatory genes were tested, and the protein levels of alpha smooth muscle actin (α-SMA) and signal transducers and activators of transcription 3 (STAT3) were analyzed. The in vitro experiments were conducted using HSC-T6 and RAW264.7 cell lines. Results: Treatment with AHWE significantly reversed histopathological liver damage and liver function abnormalities in CCl(4) mouse model. Also, the serum levels of ALT, AST, Col I, and HYP in CCl(4)-induced HF mice were improved in AHWE treatment. Further, AHWE showed a remarkable inhibitory effect on the expression of fibrosis markers (Acta2, Col1a1, and Col3a1) and inflammatory factors (Stat3, Tnfa, Il6, and Il1b) induced by CCl(4). The results of in vitro experiments were consistent with those obtained in vivo. In addition, it is shown that STAT3 signaling was involved in the anti-fibrotic effects of AHWE as evidenced by STAT3 overexpression. Conclusion: The present study proposed a novel ethnomedicine for HF and suggested the underlying role of STAT3 signaling pathway regulation in this anti-fibrotic effect of the proposed medicine. These findings would serve as solid scientific evidence in support of the development of AHWE as a novel alternative or complementary therapy for HF prevention and treatment.
format Online
Article
Text
id pubmed-9794994
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97949942022-12-29 Yao medicine Amydrium hainanense suppresses hepatic fibrosis by repressing hepatic stellate cell activation via STAT3 signaling Wu, Bingmin Huang, Lan Wang, Yange Zeng, Lishan Lin, Ying Li, Jingyan Wang, Shaogui Zhang, Guifang An, Lin Front Pharmacol Pharmacology Ethnopharmacological relevance: Hepatic fibrosis (HF) occurs in response to chronic liver injury and may easily develop into irreversible liver cirrhosis or even liver cancer. Amydrium hainanense water extract (AHWE) is a water-soluble component extracted from the Yao medicine Amydrium hainanense (H.Li, Y.Shiao & S.L.Tseng) H.Li, which is commonly used for treating inflammatory diseases in folk. Previous evidence suggested that AHWE significantly inhibited hepatic stellate cell activation. However, little is known regarding the therapeutic effect of AHWE in HF and its underlying action mechanism. Objective: Investigation of the therapeutic effect of AHWE in HF and its underlying mechanism. Methods: The therapeutic effect of AHWE was tested in vivo using an HF mouse model via an intraperitoneal injection of carbon tetrachloride (CCl(4)). Histological evaluation of liver injury and fibrosis were tested by H&E staining and Masson’s trichrome staining. Serum levels of ALT, AST, collagen type I (Col I), and hydroxyproline (HYP) were measured. The mRNA expression of liver fibrotic and inflammatory genes were tested, and the protein levels of alpha smooth muscle actin (α-SMA) and signal transducers and activators of transcription 3 (STAT3) were analyzed. The in vitro experiments were conducted using HSC-T6 and RAW264.7 cell lines. Results: Treatment with AHWE significantly reversed histopathological liver damage and liver function abnormalities in CCl(4) mouse model. Also, the serum levels of ALT, AST, Col I, and HYP in CCl(4)-induced HF mice were improved in AHWE treatment. Further, AHWE showed a remarkable inhibitory effect on the expression of fibrosis markers (Acta2, Col1a1, and Col3a1) and inflammatory factors (Stat3, Tnfa, Il6, and Il1b) induced by CCl(4). The results of in vitro experiments were consistent with those obtained in vivo. In addition, it is shown that STAT3 signaling was involved in the anti-fibrotic effects of AHWE as evidenced by STAT3 overexpression. Conclusion: The present study proposed a novel ethnomedicine for HF and suggested the underlying role of STAT3 signaling pathway regulation in this anti-fibrotic effect of the proposed medicine. These findings would serve as solid scientific evidence in support of the development of AHWE as a novel alternative or complementary therapy for HF prevention and treatment. Frontiers Media S.A. 2022-12-14 /pmc/articles/PMC9794994/ /pubmed/36588728 http://dx.doi.org/10.3389/fphar.2022.1043022 Text en Copyright © 2022 Wu, Huang, Wang, Zeng, Lin, Li, Wang, Zhang and An. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wu, Bingmin
Huang, Lan
Wang, Yange
Zeng, Lishan
Lin, Ying
Li, Jingyan
Wang, Shaogui
Zhang, Guifang
An, Lin
Yao medicine Amydrium hainanense suppresses hepatic fibrosis by repressing hepatic stellate cell activation via STAT3 signaling
title Yao medicine Amydrium hainanense suppresses hepatic fibrosis by repressing hepatic stellate cell activation via STAT3 signaling
title_full Yao medicine Amydrium hainanense suppresses hepatic fibrosis by repressing hepatic stellate cell activation via STAT3 signaling
title_fullStr Yao medicine Amydrium hainanense suppresses hepatic fibrosis by repressing hepatic stellate cell activation via STAT3 signaling
title_full_unstemmed Yao medicine Amydrium hainanense suppresses hepatic fibrosis by repressing hepatic stellate cell activation via STAT3 signaling
title_short Yao medicine Amydrium hainanense suppresses hepatic fibrosis by repressing hepatic stellate cell activation via STAT3 signaling
title_sort yao medicine amydrium hainanense suppresses hepatic fibrosis by repressing hepatic stellate cell activation via stat3 signaling
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794994/
https://www.ncbi.nlm.nih.gov/pubmed/36588728
http://dx.doi.org/10.3389/fphar.2022.1043022
work_keys_str_mv AT wubingmin yaomedicineamydriumhainanensesuppresseshepaticfibrosisbyrepressinghepaticstellatecellactivationviastat3signaling
AT huanglan yaomedicineamydriumhainanensesuppresseshepaticfibrosisbyrepressinghepaticstellatecellactivationviastat3signaling
AT wangyange yaomedicineamydriumhainanensesuppresseshepaticfibrosisbyrepressinghepaticstellatecellactivationviastat3signaling
AT zenglishan yaomedicineamydriumhainanensesuppresseshepaticfibrosisbyrepressinghepaticstellatecellactivationviastat3signaling
AT linying yaomedicineamydriumhainanensesuppresseshepaticfibrosisbyrepressinghepaticstellatecellactivationviastat3signaling
AT lijingyan yaomedicineamydriumhainanensesuppresseshepaticfibrosisbyrepressinghepaticstellatecellactivationviastat3signaling
AT wangshaogui yaomedicineamydriumhainanensesuppresseshepaticfibrosisbyrepressinghepaticstellatecellactivationviastat3signaling
AT zhangguifang yaomedicineamydriumhainanensesuppresseshepaticfibrosisbyrepressinghepaticstellatecellactivationviastat3signaling
AT anlin yaomedicineamydriumhainanensesuppresseshepaticfibrosisbyrepressinghepaticstellatecellactivationviastat3signaling